Education
About Us
Working with TipRanks
Follow Us
Hinge Health, Inc. Class A (HNGE)
NYSE:HNGE
Top Page
Hinge Health, Inc. Class A
(NYSE:HNGE)
Select Model
Select Model
Rating:64Neutral
Price Target:
$49.00
▲(7.83% Upside)
Action:ReiteratedDate:02/17/26
The score is driven primarily by solid financial health (low leverage and strong cash flow) and a constructive earnings call with confident 2026 guidance and improving profitability outlook. Offsetting these are weak GAAP-based valuation (negative P/E) and mixed technical momentum (below key moving averages with negative MACD).
Positive Factors
Strong free cash flow generation
Sustained, materially positive free cash flow provides durable financial flexibility: it funds organic growth, product development, and the share repurchase program without leaning on debt. Strong FCF reduces refinancing risk and supports multi‑year investment in sales and clinical trials to scale MSK care.
High gross margins with accelerating revenue
Consistently high ~77–80% gross margins combined with rapid top‑line growth indicate attractive unit economics in Hinge's digital MSK model. Durable margin headroom enables operating leverage as volume scales, supporting sustainable profitability even while management invests in commercialization and product enhancements.
Large, sticky commercial footprint and operational scale
A broad contracted‑lives base, high (97%) client retention, and rapid member growth create a durable revenue foundation. Combined with AI‑driven efficiency that scaled care team capacity, this reduces marginal costs, lowers churn risk, and supports predictable revenue expansion over multiple years.
Negative Factors
Large GAAP loss and earnings volatility
A very large 2025 GAAP loss contrasts with cash strength and suggests significant non‑cash charges or one‑time items. Persistent GAAP volatility complicates assessment of normalized earnings, may hinder stakeholder confidence, and could limit flexibility if accounting adjustments recur or attract scrutiny.
Guided growth deceleration in 2026
A sizable slowdown in guided growth tightens the window for rapid market share capture and increases reliance on margin gains and new product monetization to meet investor expectations. Slower topline momentum raises execution risk that past investments will take longer to deliver returns.
Delayed monetization and low engagement yield
Key product initiatives (Hinge Select) and higher‑value channels are not expected to materially contribute until 2027, while current enrollment/engagement yield remains far below benchmarks. This delays per‑member revenue upside and makes medium‑term margin targets contingent on yield improvements and successful product monetization.
Hinge Health, Inc. Class A (HNGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.59B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth50.67%
EPS Growth-578.00%
CountryUS
Employees1,514
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.49
Shares Outstanding55,816,216
10 Day Avg. Volume1,386,883
30 Day Avg. Volume1,650,511
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.72
Price to Sales (P/S)6.26
P/FCF Ratio21.54
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.62
Enterprise Value/Gross Profit7.05
Enterprise Value/Ebitda-6.26
Forecast
1Y Price Target
$59.77Price Target Upside31.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.91
Revenue Forecast (FY)$736.60M
Hinge Health, Inc. Class A Business Overview & Revenue Model
Company DescriptionHinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.
How the Company Makes MoneyPublicly verifiable details about Hinge Health, Inc. Class A (HNGE)’s specific revenue model (e.g., pricing structure, exact revenue streams, customer mix, contract terms, or partnership economics) are not available in the information provided here; therefore, a detailed factual explanation cannot be given without risking invention. null
Hinge Health, Inc. Class A Earnings Call Summary
Earnings Call Date:Feb 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational and financial momentum: robust revenue growth, high margins, exceptional free cash flow generation, meaningful AI-driven efficiency gains, high retention, and large commercial expansion (24.6M contracted lives). Management provided confident 2026 guidance while noting deliberate investments and conservatism (e.g., limited near-term revenue from Hinge Select and flat ASP assumptions). Key risks and watch items include slower guided growth in 2026 versus 2025, still-low engagement yield relative to long-term benchmarks, delayed monetization of Hinge Select, and potentially confusing buyback disclosures that reduced cash. Overall, positive execution and durability of the business were the dominant themes, with a few strategic and timing-related caveats to monitor.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Q4 revenue of $171M, up 46% year-over-year; full year 2025 revenue of $588M, up 51% year-over-year; LTM calculated billings of $671M, up 44% year-over-year.
Exceptional Profitability and Cash Generation
Q4 operating margin of 28% and full year 2025 operating margin of 20% (vs negative 7% in 2024); generated $62M free cash flow in Q4 and $180M for the full year 2025, representing a 36% and 31% free cash flow margin respectively.
Industry-Leading Efficiency (Rule of 40)
Rule of 40 metric of 82 in Q4 and 81 for full year 2025 — more than double the 40 standard, driven by high growth and strong free cash flow margins.
Rapid Commercial Expansion
Added ~4.8M net new contracted lives in 2025 to reach ~24.6M contracted lives across ~2,800 clients (25% YoY client growth); ended 2025 with ~783,000 active members, a 47% increase year-over-year.
Yield and Engagement Improvements
Yield (enrollment/engagement) improved over 50 basis points from 3.4% at end-2024 to 3.9% at end-2025; lifetime member activity surpassed 100M sessions with 41M sessions in 2025 (about 52 sessions per active member annualized).
Operational Leverage from AI
Served 47% more members in 2025 while keeping care team costs flat; average asynchronous care team time fell 28% from March 2025 in one quarter; AI care assistant 'Robin' has a 92% positive rating among early users.
High Retention and Clinical Validation
Annual client retention of 97% in 2025; net dollar retention well above 110%; published 21st peer‑reviewed outcomes study showing 60% fewer imaging visits for chronic back program participants at three months versus control.
Confident 2026 Guidance and Capital Position
Q1 2026 revenue guide $171–173M (approx. 39% YoY at midpoint); full year 2026 revenue guide $732–742M (approx. 25% YoY at midpoint), and projected non-GAAP operating margin ~21% for 2026. End-of-quarter cash and equivalents $479M and board authorized share repurchase program (up to $250M).
Negative Updates
Slower Growth Assumed for 2026
Management guided to ~25% year-over-year revenue growth for full year 2026 (midpoint), down from 51% growth in 2025, reflecting deceleration versus last year.
Limited Near-Term Revenue from Hinge Select
Hinge Select (high-performance provider network) shows promising early outcomes but management does not expect meaningful revenue contribution until at least 2027.
Engagement Yield Still Low Relative to Long-Term Benchmark
End-of-2025 yield was 3.9% (up from 3.4%), well below the cited long-term benchmark of ~9% of U.S. adults who see a physical therapist — indicating material runway but current reliance on improving yield.
Share Repurchase and Cash Deployment Ambiguity
Transcript reports a board authorization of up to $250M for repurchases but also states repurchasing 1.4M shares for $665M in Q4 and ending cash of $479M (down from $497M). The repurchase activity reduced cash and raised questions about buyback magnitude and consistency with authorization.
Pricing and ASPs Largely Flat
Average selling price remained essentially flat in 2025 and guidance assumes flat ASP in 2026, limiting near-term revenue upside from price expansion despite engagement gains.
Uncertain Timing for Medicare/Access Program Impact
Potential opportunity from CMS Access program and traditional Medicare exists, but management does not expect meaningful contribution in 2026 and views material impact as 2027 or later; program details and pricing remain uncertain.
Company Guidance
Hinge Health guided Q1 2026 revenue of $171M–$173M (about 39% YoY growth at the midpoint) with non‑GAAP income from operations of $30M–$32M (roughly an 18% margin at the midpoint), noting Q1 is their lowest‑margin quarter due to client launches; for full‑year 2026 they expect revenue of $732M–$742M (≈25% YoY growth at the midpoint and $39M above sell‑side consensus) and non‑GAAP income from operations of $151M–$156M (≈21% margin at the midpoint, ~$18M above consensus and ~100 bps better than 2025 despite planned investments). Assumptions include average LTM eligible lives of 24.4M, flat yield and essentially flat average selling price, an anticipated ~100 bps gross margin improvement in 2026, GAAP diluted weighted average shares of 85–87M (excluding buybacks), and an expectation to be GAAP profitable in 2026.Hinge Health, Inc. Class A Financial Statement Overview
Summary
Strong top-line expansion and consistently high gross margins, plus a low-debt balance sheet and sharply improving operating/free cash flow. The main offset is earnings quality/volatility—2025 shows a very large GAAP net loss despite strong cash generation, creating uncertainty about normalized profitability.Income Statement
Revenue growth is strong, accelerating from ~33% (2024) to ~1,001% (2025), and gross margins are consistently high (~77–80%), indicating an attractive unit economics profile. However, profitability deteriorated sharply in 2025 with a very large net loss (net margin ~-90%) versus only a modest loss in 2024 (~-3%), suggesting a major cost ramp, one-time charges, or a scalability setback. Overall: excellent top-line and gross profit profile, but severe earnings volatility and weak bottom-line performance.36
Negative
Balance Sheet
The balance sheet looks conservatively levered, with very low total debt (~$8–16M) against sizable equity (~$379–427M) across periods, implying ample balance-sheet flexibility. Total assets grew (to ~$745M in 2025), supporting capacity to invest in growth. The key weakness is returns: equity returns were negative in 2023–2024 (and not meaningfully positive thereafter), consistent with ongoing losses and questions about sustainable profitability.74
Positive
Cash Flow
Cash generation improved materially: operating cash flow swung from negative in 2023 (-$64M) to positive in 2024 ($49M) and surged in 2025 ($171M), with free cash flow closely tracking operating cash flow (2025 free cash flow ~$171M). Free cash flow growth is strong (2025 ~21% vs 2024). The main concern is the disconnect between strong cash flow and the very large 2025 accounting loss, which could indicate heavy non-cash charges or working-capital timing that may not be fully repeatable.78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 587.86M | 390.40M | 292.73M |
| Gross Profit | 468.22M | 300.59M | 194.18M |
| EBITDA | -541.24M | -5.31M | -102.92M |
| Net Income | -528.26M | -11.93M | -108.14M |
Balance Sheet | |||
| Total Assets | 744.76M | 673.26M | 622.53M |
| Cash, Cash Equivalents and Short-Term Investments | 363.86M | 466.57M | 423.36M |
| Total Debt | 8.04M | 11.07M | 15.73M |
| Total Liabilities | 366.23M | 256.56M | 195.25M |
| Stockholders Equity | 378.54M | 416.70M | 427.28M |
Cash Flow | |||
| Free Cash Flow | 170.73M | 45.23M | -68.52M |
| Operating Cash Flow | 171.44M | 49.00M | -63.91M |
| Investing Cash Flow | -113.76M | 18.31M | 1.50M |
| Financing Cash Flow | -150.47M | -2.20M | -3.00M |
Hinge Health, Inc. Class A Risk Analysis
Hinge Health, Inc. Class A disclosed 82 risk factors in its most recent earnings report. Hinge Health, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hinge Health, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $3.59B | -6.96 | -132.16% | ― | 50.67% | -578.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.97M | -0.18 | -145.57% | ― | ― | 97.70% | |
46 Neutral | $8.07M | -0.90 | -220.42% | ― | -41.03% | 35.71% | |
45 Neutral | $2.25M | -0.37 | -202.20% | ― | -49.63% | 82.22% | |
40 Underperform | $505.13K | -2.13 | ― | ― | -8.57% | -52.17% |
* Healthcare Sector Average
HNGE
Hinge Health, Inc. Class A
44.46
4.30
10.71%
ERNA
Eterna Therapeutics
0.31
-3.51
-91.91%
MSPR
MSP Recovery
0.03
-12.01
-99.74%
BJDX
Bluejay Diagnostics
1.98
-13.94
-87.56%
TIVC
Tivic Health Systems
0.92
-2.26
-71.10%
HSCS
Heart Test Laboratories, Inc.
2.54
-0.50
-16.45%
Hinge Health, Inc. Class A Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
Hinge Health Posts Record 2025 Results With Strong Profitability
Positive
Feb 10, 2026
Hinge Health reported record fourth-quarter and full-year 2025 results on February 10, 2026, highlighted by 46% year-on-year revenue growth in Q4 to $170.7 million, expanded gross margins and sharply higher operating income and cash generation. For 2025, revenue rose 51% to $587.9 million, non-GAAP operations swung to a $119.5 million profit, free cash flow nearly quadrupled and key operating metrics, including clients, contracted lives and members, all posted strong double-digit growth.
The company’s Rule of 40 metric improved to 81 from 45, underscoring a rare combination of rapid growth and rising profitability in digital health, while cash and investments reached $478.8 million at year-end. Management also highlighted a $250 million share repurchase program authorized in November 2025, of which $65 million was deployed in the fourth quarter, signaling confidence in the business and offering potential upside for shareholders as Hinge Health consolidates its leadership in the musculoskeletal segment.
The most recent analyst rating on (HNGE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Hinge Health, Inc. Class A stock, see the HNGE Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.